Treating patient-derived DCs with EVs from lung cancer patients induced the accumulation of indoleamine 2,3-dioxygenase (IDO), a marker of tolerogenic DCs, in 80% of cells, compared to 65% of DCs treated with EVs from lung cancer patients with chronic inflammation. This evidence concerns the gene IDO1 and lung cancer.